BnH-015B
/ BnH Research
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
October 07, 2025
Positive modulation of NMDA receptors in the hippocampus ameliorates Alzheimer's disease phenotypes via IL-33/ST-2/OPN signaling in APP/PS1 mice.
(Neuroscience 2025)
- "Recently approved antiamyloid monoclonal antibodies—exemplified by lecanemab (Leqembi)—lower brain amyloid burden and produce moderately less cognitive decline versus placebo, but their safety profile reflects modality-specific liabilities, notably amyloid-related imaging abnormalities (ARIA) and infusion reactions; ARIA is recognized by the FDA as a class effect of antibodies targeting amyloid and is highlighted with a boxed warning on the Leqembi label. Finally, BnH-015B-treated mice exhibited significantly improved performance of hippocampus-dependent spatial learning and memory compared to vehicle-treated controls. These results suggest that Positive modulation of NMDA receptors in the hippocampus may rescue Hebbian synaptic plasticity and cognitive deficit, as well as amyloid-beta deposit via IL-33/ST-2/OPN signaling in the rodent Alzheimer's disease model."
Late-breaking abstract • Preclinical • Alzheimer's Disease • CNS Disorders • GRIN2B • IL33 • SPP1
January 07, 2025
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
(clinicaltrials.gov)
- P1 | N=92 | Recruiting | Sponsor: BnH Research | Not yet recruiting ➔ Recruiting
Enrollment open • Alzheimer's Disease • CNS Disorders
August 02, 2024
BnH-015B Clinical Trial in Moderate Alzheimer's Disease
(clinicaltrials.gov)
- P1 | N=92 | Not yet recruiting | Sponsor: BnH Research
New P1 trial • Alzheimer's Disease • CNS Disorders
1 to 3
Of
3
Go to page
1